AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36114704 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 233
Study 36114704 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 233
Study 33754794 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels ≤1000 pg/mL in obese patients
Number of subjects: 0
Study 33754794 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels ≤1000 pg/mL in nonobese patients
Number of subjects: 0
Study 33754794 — intervention group
Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 0
Study 33026823 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (15 mcg/kg) administered intravenously
Number of subjects: 8
Study 33026823 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8
Study 33033996 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAP (Enhanced Adherence Package)
Number of subjects: 454
Study 33033996 — intervention group
Group type: COMPARATOR
Intervention: SOC (Standard of Care)
Number of subjects: 454
Study 32091400 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month P2Y12 inhibitor therapy
Number of subjects: 210
Study 32091400 — intervention group
Group type: COMPARATOR
Intervention: Six-month P2Y12 inhibitor therapy
Number of subjects: 210
Study 33865446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab (10 mg/kg biweekly)
Number of subjects: 854
Study 33865446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 854
Study 33587220 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health indicators
Number of subjects: 1519
Study 33587220 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective health measures
Number of subjects: 1519
Study 33231534 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized ACT
Number of subjects: 60
Study 33231534 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-personalized ACT
Number of subjects: 60
Study 33231534 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 34906125 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-jaw group (Group V-J)
Number of subjects: 60
Study 34906125 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-virtual group (Group J-V)
Number of subjects: 60
Study 34906125 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality group (Group V)
Number of subjects: 60
Study 34906125 — intervention group
Group type: COMPARATOR
Intervention: Traditional jaw model group (Group J)
Number of subjects: 60
Study 34581430 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-guided ticagrelor dosing
Number of subjects: 374
Study 34581430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 374
Study 33836436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trialogical contact-based intervention
Number of subjects: 1318
Study 33704653 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle insertion at epineurium
Number of subjects: 6
Study 33704653 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle insertion at subepineurium
Number of subjects: 6
Study 33704653 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle contact with nerve
Number of subjects: 6
Study 33704653 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle penetration of nerve
Number of subjects: 6
Study 33704653 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle insertion
Number of subjects: 6
Study 32790539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 0
Study 32790539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34767246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Number of subjects: 106
Study 34767246 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing intervention
Number of subjects: 106
Study 33237551 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L questionnaire
Number of subjects: 1020
Study 33237551 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 1020
Study 35713975 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric sinusoidal oscillations (equal amplitude, differing velocities)
Number of subjects: 25
Study 35713975 — intervention group
Group type: COMPARATOR
Intervention: Symmetric sinusoidal oscillations
Number of subjects: 25
Study 35713975 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric condition
Number of subjects: 25
Study 35713975 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric stimulation
Number of subjects: 25
Study 33443580 — intervention group
Group type: EXPERIMENTAL
Intervention: aIIV3
Number of subjects: 757
Study 33443580 — intervention group
Group type: COMPARATOR
Intervention: HD-IIV3
Number of subjects: 757
Study 36293912 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (350 mL)
Number of subjects: 32
Study 36293912 — intervention group
Group type: COMPARATOR
Intervention: Water (350 mL)
Number of subjects: 32
Study 33541567 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training + Eurycoma longifolia
Number of subjects: 45
Study 33541567 — intervention group
Group type: COMPARATOR
Intervention: Control + Eurycoma longifolia
Number of subjects: 45
Study 33541567 — intervention group
Group type: COMPARATOR
Intervention: Concurrent training + placebo
Number of subjects: 45
Study 33541567 — intervention group
Group type: COMPARATOR
Intervention: Control + placebo
Number of subjects: 45
Study 35239723 — intervention group
Group type: COMPARATOR
Intervention: Text-based message (TM)
Number of subjects: 477
Study 35239723 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based message and personalised video story (TM+VS)
Number of subjects: 477
Study 35239723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TM and TM+VS)
Number of subjects: 477
Study 34480563 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoids (methylprednisolone 10 mg/kg)
Number of subjects: 174
Study 34480563 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose glucocorticoids (dexamethasone 8 mg)
Number of subjects: 174
Study 35230622 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct‐to‐patient message through the EHR portal with HCV antibody lab order
Number of subjects: 1600
Study 35230622 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 1600
Study 33245288 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) - Awareness + Connection
Number of subjects: 343
Study 33245288 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) - Awareness + Insight
Number of subjects: 343
Study 33245288 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 343
Study 35688328 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation (UPSF)
Number of subjects: 48
Study 35688328 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation (BPSF)
Number of subjects: 48
Study 33452448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (RM)
Number of subjects: 138
Study 33452448 — intervention group
Group type: COMPARATOR
Intervention: Non-maintenance (NM)
Number of subjects: 138
Study 32359745 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered Nigella sativa seeds
Number of subjects: 40
Study 35085877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (Oxy)
Number of subjects: 151
Study 35085877 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (APAP)
Number of subjects: 151
Study 35085877 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Oxy vs APAP
Number of subjects: 151
Study 33684641 — intervention group
Group type: EXPERIMENTAL
Intervention: BHV-1 seropositive camels (detected by ELISA)
Number of subjects: 865
Study 33684641 — intervention group
Group type: EXPERIMENTAL
Intervention: Herd seroprevalence
Number of subjects: 865
Study 33684641 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for BHV-1 infection
Number of subjects: 865
Study 33684641 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of risk factors
Number of subjects: 865
Study 35179251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 150 mg BID orally
Number of subjects: 24
Study 32585741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of pinprick therapy with super pulse fractional CO2 laser
Number of subjects: 20
Study 32585741 — intervention group
Group type: COMPARATOR
Intervention: Super pulse fractional CO2 laser
Number of subjects: 20
Study 32678787 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + DRT
Number of subjects: 29
Study 32678787 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT
Number of subjects: 29
Study 32678787 — intervention group
Group type: COMPARATOR
Intervention: Driving simulation task
Number of subjects: 29
Study 35287831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered education (two sessions of 45-60 minutes)
Number of subjects: 104
Study 35287831 — intervention group
Group type: COMPARATOR
Intervention: Usual education
Number of subjects: 104
Study 32132512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringers (LR)
Number of subjects: 1581
Study 32132512 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 1581
Study 35728488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocalization maneuver during the second stage of labor
Number of subjects: 0
Study 35728488 — intervention group
Group type: COMPARATOR
Intervention: Routine humanized vaginal deliveries
Number of subjects: 0
Study 35829935 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 mg and Tamoxifen 20 mg (A + T)
Number of subjects: 234
Study 35829935 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 mg (A-150)
Number of subjects: 234
Study 35829935 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib 200 mg and prophylactic loperamide (A-200)
Number of subjects: 234
Study 34152787 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-promoting program
Number of subjects: 264
Study 34152787 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education control
Number of subjects: 264
Study 33197225 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + bevacizumab (atezo + bev)
Number of subjects: 0
Study 33197225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (sorafenib or lenvatinib)
Number of subjects: 0
Study 33197225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor (second-line therapy)
Number of subjects: 0
Study 33197225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib, regorafenib, ramucirumab, atezo + bev (second-line therapy)
Number of subjects: 0
Study 33197225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab or nivolumab (second-line therapy)
Number of subjects: 0
Study 33197225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab (second-line and third-line therapy)
Number of subjects: 0
Study 35942243 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt with Job's tears (200 ml daily)
Number of subjects: 60
Study 35942243 — intervention group
Group type: COMPARATOR
Intervention: Yogurt alone (containing Lactobacillus acidophilus La5 and Bifidobacterium Bb12)
Number of subjects: 60
Study 33247996 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 400
Study 33598767 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 30
Study 33598767 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 33598767 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 30
Study 32958203 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 69
Study 32958203 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 69
Study 35916505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (LTVV, Vt = 5 mL/kg along with 5 cm of H2O PEEP)
Number of subjects: 28
Study 35916505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (LTVV)
Number of subjects: 28
Study 35916505 — intervention group
Group type: COMPARATOR
Intervention: MCC950 (an inhibitor of NLRP3)
Number of subjects: 28
Study 35916505 — intervention group
Group type: COMPARATOR
Intervention: High-tidal-volume ventilation (Vt = 10 mL/kg without PEEP)
Number of subjects: 28
Study 34924001 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Outcome Sets (COS)
Number of subjects: 62
Study 34924001 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to using COS
Number of subjects: 62
Study 34924001 — intervention group
Group type: EXPERIMENTAL
Intervention: Enablers to using COS
Number of subjects: 62
Study 34676577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 513
Study 34676577 — intervention group
Group type: COMPARATOR
Intervention: Control (CO)
Number of subjects: 513
Study 32164792 — intervention group
Group type: EXPERIMENTAL
Intervention: LiuZiJue Qigong (LQG) combined with conventional rehabilitation therapy
Number of subjects: 160
Study 32164792 — intervention group
Group type: COMPARATOR
Intervention: Traditional core stability training combined with conventional rehabilitation therapy
Number of subjects: 160
Study 35621277 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-based surveillance
Number of subjects: 106
Study 34169328 — intervention group
Group type: EXPERIMENTAL
Intervention: Home prehabilitation
Number of subjects: 20
Study 34169328 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 32711801 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 387
Study 32711801 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 387
Study 32711801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 35417316 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC training while sitting (ROC-Sit)
Number of subjects: 38
Study 35417316 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC training while standing (ROC-Stand)
Number of subjects: 38
Study 35417316 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 38
Study 33430950 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigate online decision aid
Number of subjects: 304
Study 33430950 — intervention group
Group type: COMPARATOR
Intervention: Control arm (website of Australia’s peak national body for prostate cancer)
Number of subjects: 304
Study 32912441 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization in patients with QCA stenosis ≥60%
Number of subjects: 3851
Study 32912441 — intervention group
Group type: COMPARATOR
Intervention: Control group in patients with QCA stenosis <60%
Number of subjects: 3851
Study 34562781 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Seat (BoseRide® electro‐magnetic active seat)
Number of subjects: 276
Study 34562781 — intervention group
Group type: COMPARATOR
Intervention: Passive Seat (new version of current passive air suspension seat)
Number of subjects: 276
Study 33835597 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily monetary incentives + self-monitoring
Number of subjects: 0
Study 33835597 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed lump sum monetary incentives + self-monitoring
Number of subjects: 0
Study 33835597 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring only
Number of subjects: 0
Study 32811461 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (SP)
Number of subjects: 51
Study 32811461 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 51
Study 36124312 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus nutrition program (Ex + Nt group, n = 36)
Number of subjects: 72
Study 36124312 — intervention group
Group type: COMPARATOR
Intervention: Exercise program (Ex group, n = 36)
Number of subjects: 72
Study 33021044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (2 mg) after high-fat, high-calorie meal
Number of subjects: 12
Study 33021044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (2 mg) after moderate-fat, moderate-calorie meal
Number of subjects: 12
Study 33021044 — intervention group
Group type: COMPARATOR
Intervention: Vilaprisan (2 mg) under fasting conditions
Number of subjects: 12
Study 616636653 — intervention group
Group type: EXPERIMENTAL
Intervention: study‐test‐study (S‐T‐S) using a blocked order
Number of subjects: 0
Study 616636653 — intervention group
Group type: EXPERIMENTAL
Intervention: study‐test‐study (S‐T‐S) using an interleaved order
Number of subjects: 0
Study 616636653 — intervention group
Group type: COMPARATOR
Intervention: study‐study‐study (S‐S‐S) using a blocked order
Number of subjects: 0
Study 616636653 — intervention group
Group type: COMPARATOR
Intervention: study‐study‐study (S‐S‐S) using an interleaved order
Number of subjects: 0
Study 35156404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring Before Exposure (CR Before)
Number of subjects: 93
Study 35156404 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Restructuring After Exposure (CR After)
Number of subjects: 93
Study 35156404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR Before and CR After
Number of subjects: 93
Study 33813753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (ZOL) administered 6 months after last denosumab
Number of subjects: 61
Study 33813753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (ZOL) administered 9 months after last denosumab
Number of subjects: 61
Study 33813753 — intervention group
Group type: COMPARATOR
Intervention: Observation group (OBS)
Number of subjects: 61
Study 32981695 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg once daily
Number of subjects: 367
Study 32981695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 35863099 — intervention group
Group type: EXPERIMENTAL
Intervention: PENPal‐HF plus usual care
Number of subjects: 30
Study 35863099 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 33761535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT)
Number of subjects: 50
Study 32739444 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of cultural dexterity skills by residents
Number of subjects: 494
Study 32739444 — intervention group
Group type: COMPARATOR
Intervention: Patient perception of culturally dexterous care
Number of subjects: 494
Study 32739444 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identification of residents' cultural dexterity
Number of subjects: 494
Study 32739444 — intervention group
Group type: COMPARATOR
Intervention: Patient reports of culturally dexterous care by race
Number of subjects: 494
Study 35486027 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Number of subjects: 96
Study 35486027 — intervention group
Group type: COMPARATOR
Intervention: Mucosal Advancement Flap (MAF)
Number of subjects: 96
Study 33369680 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural‐based physical activity intervention (12 weeks, 8 face-to-face sessions, 12 weekly phone calls, Fitbit tracking)
Number of subjects: 134
Study 33369680 — intervention group
Group type: COMPARATOR
Intervention: Standard care (sign-posting to fatigue websites)
Number of subjects: 134
Study 34473238 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel digital ostectomy template (DOT) in Group B
Number of subjects: 20
Study 34473238 — intervention group
Group type: COMPARATOR
Intervention: Conventional digital ostectomy template (DOT) in Group A
Number of subjects: 20
Study 37682422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks (q2w)
Number of subjects: 1596
Study 37682422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 4 weeks (q4w)
Number of subjects: 1596
Study 37682422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Tralokinumab withdrawal)
Number of subjects: 1596
Study 37682422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab treatment beyond Week 16 to Week 52
Number of subjects: 1596
Study 33483226 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon Angioplasty (DCB)
Number of subjects: 120
Study 33483226 — intervention group
Group type: COMPARATOR
Intervention: Plain-Balloon Angioplasty (PTA)
Number of subjects: 120
Study 32542818 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day curcuminoids co‐administered with 5 mg/day piperine for 7 days
Number of subjects: 62
Study 32542818 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 7 days
Number of subjects: 62
Study 32406798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy intervention (12 weekly sessions)
Number of subjects: 13
Study 32406798 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy only (Control)
Number of subjects: 13
Study 32594273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine and theanine
Number of subjects: 28
Study 32594273 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 34201686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture (BVA)
Number of subjects: 60
Study 34201686 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - loxoprofen (180 mg daily)
Number of subjects: 60
Study 34201686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of BVA and NSAIDs
Number of subjects: 60
Study 34201686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 33638690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (LLBFR) resistance training (n=10)
Number of subjects: 20
Study 33638690 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20
Study 33262523 — intervention group
Group type: EXPERIMENTAL
Intervention: Branching evolution pattern
Number of subjects: 178
Study 33262523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of gain(1q) at relapse
Number of subjects: 178
Study 35239083 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator ACT (Acceptance and Commitment Therapy group intervention)
Number of subjects: 94